REG - Aptamer Group PLC - Response to Share Price Movement

AptamerAnnouncement

14/06/2023 12:30

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230614:nRSN7304Ca&default-theme=true

RNS Number : 7304C  Aptamer Group PLC  14 June 2023

14 June 2023

 

Aptamer Group plc

("Aptamer" or "the Group")

 

Response to Share Price Movement

 

Aptamer Group plc (AIM: APTA), the developer of novel Optimer(®) binders
to enable innovation in the life sciences industry, notes the significant
increase in the share price today. Other than the non-regulatory announcement
earlier today regarding the Group's partnership with NeuroBio to develop
Optimers for a potential Alzheimer's disease diagnostic, the Group is not
aware of any material commercial or operational reason for the significant
increase in its share price.

As notified in the Trading Update on 5 May 2023, Aptamer continues to explore
a range of funding options including non-dilutive and dilutive sources to
strengthen the balance sheet. Cash at the end of May 2023 stood at £0.7m.

- ENDS -

 

For further information, please contact:

 

Aptamer Group plc

Dr Rob Quinn
 
   +44 (0) 1904 217 404

SPARK Advisory Partners Limited - Nominated Adviser

Andrew Emmott / Adam
Dawes
+44 (0) 20 3368 3550

Liberum Capital Limited - Broker

Richard Lindley / Ben Cryer / Cara Murphy
 
                   +44 (0) 20 3100 2000

Consilium Strategic Communications

Matthew Neal / Chris Welsh / Lucy Featherstone
                    +44 (0) 20 3709 5700

aptamergroup@consilium-comms.com (mailto:aptamergroup@consilium-comms.com)

 

About Aptamer Group plc

Aptamer (http://www.aptamergroup.com/) Group develops custom affinity binders
through its proprietary Optimer(®) platform to enable new approaches in
therapeutics, diagnostics, and research applications. The Company strives to
deliver transformational solutions that meet the needs of life science
researchers and developers through the use of its proprietary Optimer
platform.

Optimer binders are oligonucleotide affinity ligands that can function as an
antibody alternative. The global affinity ligand market is currently worth
over $170 billion. Optimer binders are engineered to address many of the
issues found with alternative affinity molecules, such as antibodies, and
offer new, innovative solutions to bioprocessing, diagnostic and
pharmaceutical scientists.

Aptamer Group has successfully delivered projects for global pharma companies,
diagnostic development companies, and research institutes covering a range of
targets and applications with the objective of establishing royalty-bearing
licenses. Through the unique Optimer technology and processes, scientists and
collaborators can make faster, more informed decisions that support discovery
and development across the Life Sciences.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RSPEAFKLFFDDEFA